Editas Medicine (EDIT) Reports Q3 Loss of $0.66

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.66), versus ($0.32) reported last year.

"Our momentum in 2019 remains strong in advancing our pipeline of in vivo CRISPR and engineered cell medicines," said Cynthia Collins, Chief Executive Officer of Editas Medicine. “We announced this morning an amended agreement with Celgene to further expand and accelerate our oncology pipeline. In hemoglobinopathies, we look forward to presenting in vivo pre-clinical data for EDIT-301 at ASH that supports its potential as a best-in-class medicine. Finally, we eagerly anticipate first patient dosing with EDIT-101 for LCA10 in the coming months.”

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• JELD-WEN Expands Environmental Product Declaration Portfolio